Early neurotransmission impairment in non-invasive Alzheimer Disease detection

Sci Rep. 2020 Oct 2;10(1):16396. doi: 10.1038/s41598-020-73362-z.

Abstract

Alzheimer Disease (AD) is a pathology suffered by millions of people worldwide and it has a great social and economic impact. Previous studies reported a relationship between alterations in different amino acids and derivatives involved in neurotransmission systems and cognitive impairment. Therefore, in this study the neurotransmission impairment associated to early AD has been evaluated. For this purpose, different amino acids and derivatives were determined in saliva samples from AD patients and healthy subjects, by means of an analytical method based on chromatography coupled to tandem mass spectrometry. Results showed statistically significant differences in salivary levels for the compounds myo-inositol, creatine and acetylcholine; and other compounds (myo-inositol, glutamine, creatine, acetylcholine) showed significant correlations with some cognitive tests scores. Therefore, these compounds were included in a multivariate analysis and the corresponding diagnosis model showed promising indices (AUC 0.806, sensitivity 61%, specificity 92%). In conclusion, some amino acids and derivatives involved in neurotransmission impairment could be potential biomarkers in early and non-invasive AD detection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / metabolism
  • Aged
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology*
  • Amino Acids / metabolism
  • Biomarkers / metabolism
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / physiopathology*
  • Creatine / metabolism
  • Female
  • Humans
  • Inositol / metabolism
  • Male
  • Middle Aged
  • Sensitivity and Specificity
  • Synaptic Transmission / physiology*

Substances

  • Amino Acids
  • Biomarkers
  • Inositol
  • Creatine
  • Acetylcholine